Zobrazeno 1 - 10
of 180
pro vyhledávání: '"Antonio, Passaro"'
Autor:
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, Riccardo Asnaghi, Ambra Carnevale Schianca, Pamela Trillo Aliaga, Ester Del Signore, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 31, Iss 9, Pp 5121-5139 (2024)
The ever-growing knowledge regarding NSCLC molecular biology has brought innovative therapies into clinical practice; however, the treatment situation in the non-metastatic setting is rapidly evolving. Indeed, immunotherapy-based perioperative treatm
Externí odkaz:
https://doaj.org/article/3ed05c0b4ba740369ca1630364d8a082
Autor:
Gianluca Spitaleri, Pamela Trillo Aliaga, Ilaria Attili, Ester Del Signore, Carla Corvaja, Chiara Corti, Edoardo Crimini, Antonio Passaro, Filippo de Marinis
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 5072-5092 (2023)
ALK translocation amounts to around 3–7% of all NSCLCs. The clinical features of ALK+ NSCLC are an adenocarcinoma histology, younger age, limited smoking history, and brain metastases. The activity of chemotherapy and immunotherapy is modest in ALK
Externí odkaz:
https://doaj.org/article/237f3ac30475444a97d7a0d94817d83b
Autor:
Francesco Petrella, Stefania Rizzo, Ilaria Attili, Antonio Passaro, Thomas Zilli, Francesco Martucci, Luca Bonomo, Filippo Del Grande, Monica Casiraghi, Filippo De Marinis, Lorenzo Spaggiari
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 3160-3175 (2023)
Lung cancer is the second-most commonly diagnosed cancer and the leading cause of cancer death worldwide. The most common histological type is non-small-cell lung cancer, accounting for 85% of all lung cancer cases. About one out of three new cases o
Externí odkaz:
https://doaj.org/article/7cd90eff1b2743afa1500462c53fc72d
Publikováno v:
Current Oncology, Vol 29, Iss 1, Pp 255-266 (2022)
Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. We conducted a systematic review to investigate the available data on this pati
Externí odkaz:
https://doaj.org/article/29d1ffb8fb6a4459804472541f12a3e7
Autor:
Ilaria Attili, Carmine Valenza, Celeste Santoro, Gabriele Antonarelli, Pamela Trillo Aliaga, Ester Del Signore, Chiara Catania, Gianluca Spitaleri, Antonio Passaro, Filippo de Marinis
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundFollowing the introduction of immunotherapy (IO) in the first-line (1L) treatment in patients with non-small cell lung cancer (NSCLC) without sensitizing EGFR/ALK mutations, increasing real-world data depict how difficult it is to replicate
Externí odkaz:
https://doaj.org/article/b82967c179b1415b8e47bb150aadac48
Autor:
James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Keunchil Park, Antonio Passaro, Filippo De Marinis, Flavio Solca, Angela Märten, Edward S. Kim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionPreviously, we developed a database of 693 patients with NSCLC and uncommon EGFR mutations treated with afatinib. Here, we provide an update of >1000 patients, with more data on specific mutations.MethodsPatients were identified from a pr
Externí odkaz:
https://doaj.org/article/06285341cf024f7fb6cee27c5cc600a1
Autor:
Antonio Passaro, Filippo de Marinis, Hai-Yan Tu, Konstantin K. Laktionov, Jifeng Feng, Artem Poltoratskiy, Jun Zhao, Eng Huat Tan, Maya Gottfried, Victor Lee, Dariusz Kowalski, Cheng Ta Yang, BJ Srinivasa, Laura Clementi, Tejaswini Jalikop, Dennis Chin Lun Huang, Agnieszka Cseh, Keunchil Park, Yi-Long Wu
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Externí odkaz:
https://doaj.org/article/9f20422dd14b455088226a15dd90831a
Autor:
Oliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, Christoph Weinlinger, Amanda Tufman, Aurélie Swalduz, Kristina Lamberg, Sayed M. S. Hashemi, Florian Huemer, Anders Vikström, Martin Wermke, Gudrun Absenger, Alfredo Addeo, Shantanu Banerji, Antonio Calles, Stephen Clarke, Massimo Di Maio, Alice Durand, Michaël Duruisseaux, Malinda Itchins, Okko-Sakari Kääränien, Florian Krenn, Eckart Laack, Adrianus Johannes de Langen, Katja Mohorcic, Georg Pall, Antonio Passaro, Gerald Prager, Achim Rittmeyer, Jeffrey Rothenstein, Michael Schumacher, Ewald Wöll, Arschang Valipour
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity in early clinical trials; however, their ef
Externí odkaz:
https://doaj.org/article/fa3f18a7c5a247f2bb673138b510d84e
Autor:
Lorenza Landi, Federica D’Incà, Alain Gelibter, Rita Chiari, Francesco Grossi, Angelo Delmonte, Antonio Passaro, Diego Signorelli, Francesco Gelsomino, Domenico Galetta, Diana Giannarelli, Hector Soto Parra, Gabriele Minuti, Marcello Tiseo, Maria Rita Migliorino, Francesco Cognetti, Luca Toschi, Paolo Bidoli, Francovito Piantedosi, Luana Calabro’, Federico Cappuzzo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sens
Externí odkaz:
https://doaj.org/article/2272c4a411464ed7ab0c54c8cd9b40b4
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age
Externí odkaz:
https://doaj.org/article/d7c925d7172a48e386618057020f7352